Pancreatic cancer

Current Opinion in Oncology

Volumn 10, Issue 4, 1998, Pages 362-366

  Brand, Randall E ^a   Tempero, Margaret A ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; GEMCITABINE;

ARTICLE; CANCER CHEMOTHERAPY; CANCER GENETICS; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; HUMAN; MAJOR CLINICAL STUDY; META ANALYSIS; MOLECULAR BIOLOGY; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PRIORITY JOURNAL; SURVIVAL RATE;

EID: 0031903413     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001622-199807000-00014     Document Type: Article

References (34)

1. Landis SH, Murray T, Bolden S, Wingo PA: Cancer statistics. 1998. CA Cancer J Clin 1998, 48:6-29.
2. Partanen TJ, Vainio HU, Ojajärvi IA, Kauppinen TP: Pancreas cancer, tobacco smoking and consumption of alcoholic beverages: a case-control study. Cancer Lett 1997, 116:27-32.
3. Fryzek JP, Garabrant DH, Harlow SD, Severson RK, Gillespie BW, Schenk M, Schottenfeld D: A case-control study of self-reported exposures to pesticides and pancreas cancer in southeastern Michigan. Int J Cancer 1997, 72:62-67.
4. Karlson BM, Ekbom A, Josefsson S, McLaughlin JK, Fraumeni JF Jr, Nyrén O: The risk of pancreatic cancer following pancreatitis: an association due to confounding? Gastroenterology 1997, 113:587-592. This study suggests that alcohol consumption, smoking, and selection b as, and not pancreatitis, are responsible for the increased risk of pancreatic cancer. A small increased risk with chronic pancreatitis could not be excluded.
5. Tavani A, Pregnolato A, Negri E, La Vecchia C: Alcohol consumption and risk of pancreatic cancer. Nutr Cancer 1997, 27:157-161.
6. Wideroff L, Gridley G, Mellemkjaer L, Chow WH, Linet M, Keehn S, et al.: Cancer incidence in a population-based cohort of patients hospitalized with diabetes mellitus in Denmark. J Natl Cancer Inst 1997, 89:1360-1365.
7. Permert J, Larsson J, Fruin AB, Tatemoto K, Herrington MK, von Schenck H, Adrian TE: Islet hormone secretion in pancreatic cancer patients with diabetes. Pancreas 1997, 15:60-68.
8. Lowenfels AB, Maisonneuve P, DiMagno EP, Elitsur Y, Gates LK Jr, Perrault J, Whitcomb DC, International Hereditary Pancreatitis Study Group: Hereditary pancreatitis and the risk of pancreatic cancer. J Natl Cancer Inst 1997, 89:442-446. A high risk of pancreatic cancer was demonstrated in patients with hereditary pancreatitis.
9. Birdwell SH, Hancock SL, Varghese A, Cox RS, Hoppe RT: Gastrointestinal cancer after treatment of Hodgkin's Disease. Int J Radiat Oncol Biol Phys 1997, 37:67-73.
10. Ji BT, Chow WH, Hsing AW, McLaughlin JK, Dai Q, Gao YT, et al.: Green tea consumption and the risk of pancreatic and colorectal cancers. Int J Cancer 1997, 70:255-258.
11. Rozenblum E, Schutte M, Goggins M, Hahn SA, Panzer S, Zahurak M, et al.: Tumor-suppressive pathways in pancreatic carcinoma. Cancer Res 1997, 57:1731-1734. An important paper reporting on the genetic alterations in pancreatic carcinoma Analysis for K-ras oncogene and DPC4. p16, and p53 tumor-suppressor genes demonstrated that the majority of tumors had multiple genetic alterations; no statistically significant association was identified between these genetic alterations and pathologic or clinical parameters.
12. Ruggeri BA, Huang L, Berger D, Chang H, Klein-Szanto AJP, Goodrow T, et al.: Molecular pathology of primary and metastatic ductal pancreatic lesions. Cancer 1997, 79:700-716.
13. Pour PM, Weide L, Liu G, Kazakoff K, Scheetz M, Toshkov I, et al.: Experimental evidence for the origin of ductal-type adenocarcinoma from the islets of langerhans. Am J Pathol 1997, 150:2167-2180.
14. Hiyama E, Kodama T, Shinbara K, Iwao T, Itoh M, Hiyama K, et al.: Telomerase activity is detected in pancreatic cancer but not in benign tumors. Cancer Res 1997, 57:326-331. The authors found telomerase activity in pancreatic cancer but not in benign lesions. Additionally, telomerase activity was detected in ductal cells from pancreatic cancer specimens, suggesting the possibility of its use in the diagnosis of cancer.
15. Iwao T, Hiyama E, Yokoyama T, Tsuchida A, Hiyama K, Murakami Y, et al.: Telomerase activity for the preoperative diagnosis of pancreatic cancer. J Natl Cancer Inst 1997, 89:1621-1623.
16. Gloor B, Todd KE, Reber HA: Diagnostic workup of patients with suspected pancreatic carcinoma. Cancer 1997, 79:1780-1786. This excellent paper from an established and recognized pancreatic surgery center describes the approach for the diagnostic evaluation of patients with suspected pancreatic carcinoma.
17. Zeman RK, Cooper C, Zeiberg AS, Kladakis A, Silverman PM, Marshall JL, et al.: TNM staging of pancreatic carcinoma using helical CT. Am J Roentgenology 1997, 169:459-464.
18. Lu DA, Reber HA, Krasny RM, Kadell BM, Sayre J: Local staging of pancreatic cancer: criteria for unresectability of major vessels as revealed by pancreatic-phase, thin-section helical CT. Am J Roentgenology 1997, 168:1439-1443. The authors report a grading system for pancreatic-phase thin-section helical CT that determines vascular unresectability in patients with pancreatic carcinoma.
19. Gress F, Savides T, Cummings O, Sherman S, Lehman G, Zaidi S, Hawes R: Radial scanning and linear array endosonography for staging pancreatic cancer: a prospective randomized comparison. Gastrointest Endosc 1997, 45:138-142.
20. Chang KJ, Nguyen P, Erickson RA, Durbin TE, Katz KD: The clinical utility of endoscopic ultrasound-guided fine-needle aspiration in the diagnosis and staging of pancreatic carcinoma. Gastrointest Endosc 1997, 45:387-393.
21. Faigel DO, Ginsberg GG, Bentz JS, Gupta PK, Smith DB, Kochman ML: Endoscopic ultrasound-guided real-time fine-needle aspiration biopsy of the pancreas in cancer patients with pancreatic lesions. J Clin Oncol 1997, 15:1439-1443.
22. Warshaw AL: Implications of peritoneal cytology for staging of early pancreatic cancer. Am J Surg 1991, 161:26-30.
23. Leach SD, Rose JA, Lowy AM, Lee JE, Charnsangavej C, Abbuzzese JL, et al.: Significance of peritoneal cytology in patients with potentially resectable adenocarcinoma of the pancreatic head. Surgery 1995, 118:472-478.
24. Johnson DW, Pendurthi TK, Balshem AM, Ross E, Litwin S, Eisenberg BL, Hoffman JP: Implications of fine-needle aspiration in patients with resectable pancreatic cancer. Am Surg 1997, 63:675-680. The authors concluded that: preoperative FNA was safe in patients who received neoadjuvant chemoradiation.
25. Hosch SB, Knoefel WT, Metz S, Stoecklein N, Niendorf A, Broelsch CE, Izbicki JR: Early lymphatic tumor cell dissemination in pancreatic cancer: frequency and prognostic significance. Pancreas 1997, 15:154-159. This study reported on the prognostic value of detecting immunohistochemical evidence of lymph node metastasis in patients who had undergone complete tumor resection.
26. Kelson DP, Portenoy R, Thaler H, Tao Y, Brennan M: Pain as a predictor of outcome in patients with operable pancreatic carcinoma. Surgery 1997, 122:53-59. This paper showed that the presence of pain was a negative predictor of survival and resectability.
27. Conlon KC, Klimstra DS, Brennan MF: Long-term survival after curative resection for pancreatic ductal adenocarcinoma. Ann Surg 1996, 223:273-279.
28. Strasberg SM, Drebin JA, Soper NJ: Evolution and current status of the Whipple procedure: an update for gastroenterologists. Gastroenterology 1997, 113:983-994. An excellent review and update on the current status of the Whipple procedure.
29. Mosca F, Giulianotti PC, Balestracci T, Di Candio G, Peitrabissa A, Sbrana F, Rossi G: Long-term survival in pancreatic cancer: pylorus-preserving versus Whipple pancreatoduodenectomy. Surgery 1997, 122:553-566.
30. Sperti C, Pasquali C, Piccoli A, Pedrazzoli S: Recurrence after resection for ductal adenocarcinoma of the pancreas. World J Surg 1997, 21:195-200.
31. Gastrointestinal Tumor Study Group: Further evidence of effective adjuvant combined radiation and chemotherapy following curative resection of pancreatic cancer. Cancer 1987, 59:2006-2010.
32. Yeo CJ, Abrams RA, Grochow LB, Sohn TA, Ord SE, Hruban RH, et al.: Pancreaticoduodenectomy for pancreatic adenocarcinoma: postoperative adjuvant chemoradiation improves survival. Ann Surg 1997, 225:621-636. This prospective, nonrandomized study demonstrated a survival advantage with the use of postoperative adjuvant chemoradiation.
33. Spitz FR, Abbruzzese JL, Lee JE, Pisters WT, Lowy AM, Fenoglio CJ, et al.: Preoperative and postoperative chemoradiation strategies in patients treated with pancreaticoduodenectomy for adenocarcinoma of the pancreas. J Clin Oncol 1997, 15:928-937. The authors conclude that preoperative therapy was comparable with postoperative therapy, with an advantage of the former that more patients received therapy.
34. Burris III HA, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, et al.: Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997, 15:2403-2413. This important study demonstrated that gemcitabine, when compared with 5-FU, had a modest result in improving survival and appeared to be effective in improving quality of life.